Methods and systems for synthesizing biological products within biomimetic condensates that enhance the concentration of enzymes, substrates, co-factors, and other molecules involved in the synthesis. The one or more enzymes involved in catalysis can be engineered to comprise low-complexity amino acid sequences or phase separation domains that can be controlled to drive reversible liquid-liquid phase separation, wherein the resulting biomimetic condensates comprise a traversable phase boundary between their dense internal portion and the less-crowded aqueous composition within which the condensates are maintained. Alternatively, biomimetic condensates can be first formed within the aqueous composition from affinity-tagged scaffold proteins that do not take part in catalysis, but are capable of recruiting into the condensate catalytic enzymes fused to an affinity tag partner. One or more enzymes can comprise or be recruited inside of the biomimetic condensate to generate a wide variety of desired chemical products.

An anticoagulant heparin-chondroitin chimeric saccharide molecule as well as a preparation method and application thereof are disclosed. The anticoagulant heparin-chondroitin chimeric saccharide molecule has a structure as shown in formula I. The heparin-chondroitin chimeric saccharide molecule of the present disclosure has potent activities against an Xa factor and IIa, and the activity of the heparin-chondroitin chimeric saccharide molecule can be effectively neutralized by protamine, with a neutralization rate of greater than or equal to 70%. The risk of causing adverse reactions such as fatal HIT is obviously lower than that of enoxaparin and other low-molecular-weight heparins. The heparin-chondroitin chimeric saccharide molecule disclosed by the present disclosure is suitable for the preparation of a safer potent anticoagulant and antithrombotic new drug.